search

Active clinical trials for "Carcinoma, Adenosquamous"

Results 41-50 of 81

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma3 more

This phase II trial is studying how well pelvic exenteration works in treating patients with recurrent cervical cancer. Pelvic exenteration may be effective in treating recurrent cervical cancer.

Completed20 enrollment criteria

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage...

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma7 more

This phase I trial is studying the side effects and best dose of cetuximab when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving cetuximab together with cisplatin and radiation therapy may kill more tumor cells.

Completed40 enrollment criteria

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical...

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma6 more

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.

Completed74 enrollment criteria

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

Cervical Squamous Cell CarcinomaAdenosquamous Carcinoma3 more

The goal of this clinical research study is to learn if a surgical procedure called an extraperitoneal laparoscopic lymphadenectomy followed by chemotherapy and tailored radiation therapy can help to control the disease for a longer time than standard-of-care chemotherapy and whole pelvic radiation therapy.

Completed20 enrollment criteria

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical...

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma8 more

This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may be a better way treat cervical cancer.

Completed28 enrollment criteria

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma3 more

This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.

Completed58 enrollment criteria

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma4 more

This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

Completed65 enrollment criteria

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous Carcinoma1 more

Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Completed41 enrollment criteria

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage...

Lung AdenocarcinomaLung Adenosquamous Carcinoma5 more

This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving erlotinib hydrochloride together with carboplatin and paclitaxel may kill more tumor cells than giving either drug alone.

Completed27 enrollment criteria

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial AdenocarcinomaEndometrial Adenosquamous Carcinoma2 more

This phase II trial is studying the side effects of gemcitabine and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Completed47 enrollment criteria
1...456...9

Need Help? Contact our team!


We'll reach out to this number within 24 hrs